U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period Ended September 30, 2013

o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period From to .

Commission file number 000-25727

IKONICS CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota		41-0730027
(State or other jurisdiction of incorporation or organization)		(I.R.S. employer identification no.)

4832 Grand Avenue Duluth, Minnesota		55807
(Address of principal executive offices)		(Zip code)

(218) 628-2217

Issuer’s telephone number

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes x No o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o		Accelerated filer o
Non-accelerated filer (Do not check if a smaller reporting company) o		Smaller reporting company x

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practical date: Common Stock, $.10 par value - 2,008,836 shares outstanding as of October 31, 2013.

Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. Condensed Financial Statements

IKONICS CORPORATION

CONDENSED BALANCE SHEETS

	September 30		December 31
	2013		2012
	(unaudited)
ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$	1,179,498	$	967,943
Short-term investments	1,814,878		1,442,939
Trade receivables, less allowance of $42,000 in 2013 and $43,000 in 2012	1,899,714		2,060,312
Inventories	2,515,698		2,678,864
Prepaid expenses and other assets	135,768		124,983
Income taxes receivable	91,671		—
Deferred income taxes	142,000		142,000
Total current assets	7,779,227		7,417,041

PROPERTY, PLANT, AND EQUIPMENT, at cost:
Land and building	6,110,906		6,063,965
Machinery and equipment	3,690,574		3,219,598
Office equipment	742,951		700,062
Vehicles	237,488		237,488
	10,781,919		10,221,113
Less accumulated depreciation	5,171,831		4,759,235
	5,610,088		5,461,878

INTANGIBLE ASSETS, less accumulated amortization of $521,727 in 2013 and $482,107 in 2012	335,046		305,357

	$	13,724,361	$	13,184,276

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:
Accounts payable	$	660,054	$	593,922
Accrued compensation	333,289		265,822
Other accrued liabilities	97,359		81,635
Income taxes payable	—		82,152
Total current liabilities	1,090,702		1,023,531

DEFERRED INCOME TAXES	431,000		366,000

Total liabilities	1,521,702		1,389,531

STOCKHOLDERS’ EQUITY:
Preferred stock, par value $.10 per share; authorized 250,000 shares; issued none	—		—
Common stock, par value $.10 per share; authorized 4,750,000 shares; issued and outstanding 2,008,836 shares in 2013 and 1,998,475 shares in 2012	200,884		199,848
Additional paid-in capital	2,555,861		2,470,507
Retained earnings	9,445,914		9,124,390
Total stockholders’ equity	12,202,659		11,794,745
	$	13,724,361	$	13,184,276

See notes to condensed financial statements

Table of Contents

IKONICS CORPORATION

CONDENSED STATEMENTS OF INCOME (Unaudited)

	Three Months				Nine Months
	Ended September 30				Ended September 30
	2013		2012		2013		2012

NET SALES	$	4,217,125	$	4,231,235	$	12,894,142	$	12,787,939

COST OF GOODS SOLD	2,575,557		2,478,358		7,904,357		7,726,216

GROSS PROFIT	1,641,568		1,752,877		4,989,785		5,061,723
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	1,330,199		1,273,286		4,124,801		3,984,854

RESEARCH AND DEVELOPMENT EXPENSES	149,864		141,186		475,791		470,165
INCOME FROM OPERATIONS	161,505		338,405		389,193		606,704

INTEREST INCOME	1,372		2,572		5,331		9,377

INCOME BEFORE INCOME TAXES	162,877		340,977		394,524		616,081

INCOME TAX EXPENSE	46,715		112,865		73,000		207,292

NET INCOME	$	116,162	$	228,112	$	321,524	$	408,789

EARNINGS PER COMMON SHARE:
Basic	$	0.06	$	0.11	$	0.16	$	0.21

Diluted	$	0.06	$	0.11	$	0.16	$	0.21

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	2,008,836		1,989,307		2,005,702		1,986,798

Diluted	2,015,125		1,993,429		2,010,334		1,990,485

See notes to condensed financial statements.

Table of Contents

IKONICS CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

	Nine Months
	Ended September 30
	2013			2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	321,524		$	408,789
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	416,068			361,811
Amortization	39,620			41,612
Stock based compensation	10,143			13,391
Gain on disposal of property, plant and equipment	(2,979		)	—
Loss on intangible asset abandonment	—			22,324
Deferred income taxes	65,000			—
Changes in working capital components:
Trade receivables	160,598			(87,129		)
Inventories	163,166			(340,484		)
Prepaid expenses and other assets	(10,785		)	(87,101		)
Income taxes receivable	(91,671		)	59,322
Accounts payable	66,132			(43,109		)
Accrued expenses	83,191			127,169
Income taxes payable	(69,397		)	90,344
Net cash provided by operating activities	1,150,610			566,939

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(585,806		)	(372,217		)
Proceeds from disposal of property, plant and equipment	24,507			—
Purchases of intangibles	(69,309		)	(30,386		)
Purchases of short-term investments	(1,814,878		)	(1,649,988		)
Proceeds on sale of short-term investments	1,442,939			1,837,699
Net cash used in investing activities	(1,002,547		)	(214,892		)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	63,492			30,123

NET INCREASE IN CASH AND CASH EQUIVALENTS	211,555			382,170

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	967,943			1,867,165

CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	1,179,498		$	2,249,335

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for income taxes, net of taxes received of $13,026 in 2013 and $18,650 paid in 2012.	$	169,068		$	57,626

See notes to condensed financial statements.

Table of Contents

IKONICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation

The balance sheet of IKONICS Corporation (the “Company”) as of September 30, 2013, and the related statements of operations for the three and nine months ended September 30, 2013 and 2012, and cash flows for the nine months ended September 30, 2013 and 2012, have been prepared without being audited.

In the opinion of management, these statements reflect all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position of IKONICS Corporation as of September 30, 2013, and the results of operations and cash flows for all periods presented.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted. Therefore, these statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

The results of operations for interim periods are not necessarily indicative of results that will be realized for the full fiscal year.

2. Short-Term Investments

The Company’s short-term investments of approximately $1,815,000 at September 30, 2013 are comprised of fully insured certificates of deposit with original maturities ranging from three to twelve months and interest rates ranging from 0.2% to 1.0%.

3. Inventories

The major components of inventories are as follows:

	Sep 30, 2013			Dec 31, 2012

Raw materials	$	2,060,334		$	2,072,540
Work-in-progress	408,041			373,512
Finished goods	1,296,047			1,478,444
Reduction to LIFO cost	(1,248,724		)	(1,245,632		)

Total Inventory	$	2,515,698		$	2,678,864

Table of Contents

IKONICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

4. Earnings Per Common Share (EPS)

Basic EPS is calculated using net income divided by the weighted average of common shares outstanding. Diluted EPS is similar to Basic EPS except that the weighted average number of common shares outstanding is increased to include the number of additional common shares that would have been outstanding if the potential dilutive common shares, such as those shares subject to options, had been issued.

Shares used in the calculation of diluted EPS are summarized below:

	Three Months Ended
	Sep 30, 2013	Sep 30, 2012

Weighted average common shares outstanding	2,008,836	1,989,307
Dilutive effect of stock options	6,289	4,122
Weighted average common and common equivalent shares outstanding	2,015,125	1,993,429

	Nine Months Ended
	Sep 30, 2013	Sep 30, 2012

Weighted average common shares outstanding	2,005,702	1,986,798
Dilutive effect of stock options	4,632	3,687
Weighted average common and common equivalent shares outstanding	2,010,334	1,990,485

There were no anti-dilutive options outstanding during the three and nine months ended September 30, 2013 and 2012.

5. Stock-Based Compensation

The Company maintains a stock incentive plan which authorizes the issuance of up to 442,750 shares of common stock. Of those shares, 14,751 were subject to outstanding options and 115,573 were reserved for future grants at September 30, 2013. The plan provides for granting eligible participants stock options or other stock awards, as described by the plan, at option prices ranging from 85% to 110% of fair market value at the date of grant. Options granted expire up to seven years after the date of grant. Such options generally become exercisable over a one to three year period.

The Company charged compensation cost of approximately $3,800 against income for the three months ended September 30, 2013 and approximately $4,400 for the three months ended September 30, 2012. For the first nine months of 2013, the Company charged compensation cost of approximately $10,100 against income and approximately $13,400 for the same period in 2012. As of September 30, 2013, there was approximately $24,000 of unrecognized compensation cost related to unvested share-based compensation awards granted. That cost is expected to be recognized over the next three years.

The Company receives a tax deduction for certain stock option exercises during the period in which the options are exercised, generally for the excess of the market price at the time the stock options are exercised over the exercise price of the options, which increases the APIC pool, which is the amount that represents the pool of excess tax benefits available to absorb tax shortages. There were no excess tax benefits recognized during the three or nine month periods ended September 30, 2013 and 2012. The Company’s APIC pool totaled approximately $111,000 at September 30, 2013 and December 31, 2012.

Table of Contents

IKONICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

Proceeds from the exercise of stock options were approximately $63,000 and $30,000 for the nine months ended September 30, 2013 and 2012, respectively.

The fair value of options granted during the nine months ended September 30, 2013 and 2012 was estimated using the Black-Scholes option pricing model with the following assumptions:

	2013			2012
Dividend yield	0		%	0		%
Expected volatility	43.9		%	41.8		%
Expected life of option	Five Years			Five Years
Risk-free interest rate	0.7		%	0.8		%
Fair value of each option on grant date	$	4.72		$	2.73

There were 4,250 and 750 options granted during the nine months ended September 30, 2013 and 2012, respectively.

Stock option activity during the nine months ended September 30, 2013 was as follows:

			Weighted
			Average
			Exercise
	Shares		Price

Outstanding at beginning of period	21,362		$	6.72
Granted	4,250		12.56
Exercised	(10,361	)	6.13
Expired and forfeited	(500	)	12.56
Outstanding at September 30, 2013	14,751		8.62
Exercisable at September 30, 2013	7,499		7.10

The aggregate intrinsic value of all options outstanding and for those exercisable at September 30, 2013 was approximately $79,000 and $52,000, respectively.

Table of Contents

IKONICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

6. Segment Information

The Company’s reportable segments are strategic business units that offer different products and have varied customer bases. There are five reportable segments: Domestic, Export, IKONICS Imaging, Digital Texturing (DTX) and Micro-Machining. Domestic sells screen printing film, emulsions, and inkjet receptive film to distributors located in the United States and Canada. IKONICS Imaging sells photo resistant film, art supplies, glass, metal medium and related abrasive etching equipment to end user customers located in the United States and Canada. Micro-Machining provides sound deadening technology to the aerospace industry along with products and services for etched composites, ceramics, glass and silicon wafers. DTX includes products and customers related to patented and proprietary inkjet technology used for mold texturing. Export sells primarily the same products as Domestic and the IKONICS Imaging products not related to Micro-Machining or DTX. In previous periods, the segment designated as Other included both Micro-Machining and DTX. Beginning in the third quarter of 2013, the Company began to report DTX and Micro-Machining as separate segments. The accounting policies applied to determine the segment information are consistent with those included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Management evaluates the performance of each segment based on the components of divisional income, and does not allocate assets and liabilities to segments except for trade receivables which are allocated based on the previous segmentation. Financial information with respect to the reportable segments follows:

For the three months ended September 30, 2013:

					IKONICS					Micro-
	Domestic		Export		Imaging		DTX			Machining			Unalloc.			Total
Net sales	$	1,881,210	$	1,310,281	$	874,442	$	104,339		$	46,853		$	—		$	4,217,125
Cost of goods sold	1,048,869		967,923		414,656		20,774			123,335			—			2,575,557
Gross profit (loss)	832,341		342,358		459,786		83,565			(76,482		)	—			1,641,568
Selling general and adminstrative*	305,297		127,346		234,096		128,968			106,974			427,518			1,330,199
Research and development*	—		—		—		—			—			149,864			149,864
Income (loss) from operations	$	527,044	$	215,012	$	225,690	$	(45,403	)	$	(183,456	)	$	(577,382	)	$	161,505

For the three months ended September 30, 2012:

					IKONICS					Micro-
	Domestic		Export		Imaging		DTX			Machining			Unalloc.			Total
Net sales	$	1,782,944	$	1,256,669	$	958,399	$	100,879		$	132,344		$	—		$	4,231,235
Cost of goods sold	1,009,697		920,397		426,750		9,928			111,586			—			2,478,358
Gross profit	773,247		336,272		531,649		90,951			20,758			—			1,752,877
Selling general and adminstrative*	283,567		141,599		284,113		144,333			69,101			350,573			1,273,286
Research and development*	—		—		—		—			—			141,186			141,186
Income (loss) from operations	$	489,680	$	194,673	$	247,536	$	(53,382	)	$	(48,343	)	$	(491,759	)	$	338,405

Table of Contents

IKONICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

For the nine months ended September 30, 2013:

					IKONICS					Micro-
	Domestic		Export		Imaging		DTX			Machining			Unalloc.			Total
Net sales	$	5,401,082	$	4,249,218	$	2,641,047	$	333,656		$	269,139		$	—		$	12,894,142
Cost of goods sold	3,057,814		3,112,063		1,316,453		57,323			360,704			—			7,904,357
Gross profit (loss)	2,343,268		1,137,155		1,324,594		276,333			(91,565		)	—			4,989,785
Selling general and adminstrative*	972,656		448,380		773,629		340,711			328,346			1,261,079			4,124,801
Research and development*	—		—		—		—			—			475,791			475,791
Income (loss) from operations	$	1,370,612	$	688,775	$	550,965	$	(64,378	)	$	(419,911	)	$	(1,736,870	)	$	389,193

For the nine months ended September 30, 2012:

					IKONICS					Micro-
	Domestic		Export		Imaging		DTX			Machining			Unalloc.			Total
Net sales	$	5,242,685	$	4,125,540	$	2,675,982	$	347,747		$	395,985		$	—		$	12,787,939
Cost of goods sold	2,978,651		3,056,401		1,256,245		103,366			331,553			—			7,726,216
Gross profit	2,264,034		1,069,139		1,419,737		244,381			64,432			—			5,061,723
Selling general and adminstrative*	882,977		464,705		881,276		374,888			234,568			1,146,440			3,984,854
Research and development*	—		—		—		—			—			470,165			470,165
Income (loss) from operations	$	1,381,057	$	604,434	$	538,461	$	(130,507	)	$	(170,136	)	$	(1,616,605	)	$	606,704

* The Company does not allocate all general and administrative expenses or any research and development expenses to its operating segments for internal reporting.

Trade receivables by segment as of September 30, 2013 and December 31, 2012 were as follows:

	Sep 30, 2013		Dec 31, 2012

Domestic	$	922,029	$	928,698
Export	649,256		708,933
IKONICS Imaging	252,229		272,346
DTX	45,666		117,552
Micro-Machining	27,477		57,122
Unallocated	3,057		(24,339		)

Total	$	1,899,714	$	2,060,312

7. Self-Funded Medical Insurance

The Company records estimates for claim liabilities based on information provided by the third-party administrators, historical claims experience, the life cycle of claims, expected costs of claims incurred but not paid, and expected costs to settle unpaid claims. The Company regularly monitors its estimated insurance-related liabilities. Actual claims experience may differ from the Company’s estimates. Costs related to the administration of the plan and related claims are expensed as incurred. The total liability for self-funded medical insurance was $45,000 as of September 30, 2013 and $54,000 as of December 31, 2012 and is included within other accrued expenses in the consolidated balance sheets.

Table of Contents

IKONICS CORPORATION

The information presented below in Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties, including those discussed under “Factors that May Affect Future Results” below, that could cause actual results to differ materially from those projected. Because actual results may differ, readers are cautioned not to place undue reliance on these forward-looking statements. Certain forward-looking statements are indicated by italics or by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology.

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following management’s discussion and analysis focuses on those factors that had a material effect on the Company’s financial results of operations during the third quarter of 2013, the nine months ended September 30, 2013 and the same periods of 2012. It should be read in connection with the Company’s unaudited financial statements and notes thereto included in this Form 10-Q and the Company’s audited financial statements, including related notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Company’s 2012 Annual Report on Form 10-K.

Factors that May Affect Future Results

· The Company’s expectation that its effective tax rate will be 28% of pretax income for the remainder of 2013 compared to its effective tax rate of 19% recorded in the first nine months of 2013—The effective tax rate for the final three months of 2013 may be affected by changes in federal and state tax law, unanticipated changes in the Company’s financial position or the Company’s operating activities and/or management decisions could increase or decrease its effective tax rate.

· The belief that the Company’s current financial resources, line of credit, cash generated from operations and the Company’s capacity for debt and/or equity financing will be sufficient to fund current and anticipated business operations and capital expenditures. The belief that the Company’s low debt levels and available line of credit make it unlikely that a decrease in product demand would impair the Company’s ability to fund operations—Changes in anticipated operating results, credit availability, equity market conditions or the Company’s debt levels may further enhance or inhibit the Company’s ability to maintain or raise appropriate levels of cash.

· The Company’s expectations as to the level and use of planned capital expenditures and that capital expenditures will be funded with cash on hand and cash generated from operating activities—This expectation may be affected by changes in the Company’s anticipated capital expenditure requirements resulting from unforeseen required maintenance, repairs, or capital asset additions. The funding of planned or unforeseen expenditures may also be affected by changes in anticipated operating results resulting from decreased sales, lack of acceptance of new products or increased operating expenses or by other unexpected events affecting the Company’s financial position.

· The Company’s belief that its vulnerability to foreign currency fluctuations and general economic conditions in foreign countries is not significant—This belief may be impacted by economic, political and social conditions in foreign markets, changes in regulatory and competitive conditions, a change in the amount or geographic focus of the Company’s international sales, or changes in purchase or sales terms.

· The Company’s plans to continue to invest in research and development efforts, expedite internal product development and invest in technological alliances, as well as the expected focus and results of such investments—These plans and expectations may be impacted by general market conditions, unanticipated changes in expenses or sales, delays in the development of new products, technological

Table of Contents

advances, the ability to find suitable and willing technology partners or other changes in competitive or market conditions.

· The Company’s beliefs as to the future performance of its new technologies or particular segments—Actual performance may be impacted by general market conditions or conditions in particular industries in which the Company’s products are used (including the aerospace industry), changes to the competitive landscape in the industries in which the Company competes (including pricing pressures from existing or future competitors), lack of acceptance of new products or technologies or increases to raw materials costs used to produce the Company’s products.

· The Company’s efforts to grow its international business—These efforts may be impacted by economic, political and social conditions in current and anticipated foreign markets, regulatory conditions in such markets, unanticipated changes in expenses or sales, changes in competitive conditions or other barriers to entry or expansion.

· The Company’s belief as to future activities that may be undertaken to expand the Company’s business—Actual activities undertaken may be impacted by general market conditions, competitive conditions in the industries in which the Company sells products, unanticipated changes in the Company’s financial position, lack of acceptance of new products or the inability to identify attractive acquisition targets or other business opportunities.

Critical Accounting Estimates

The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America. Therefore, the Company is required to make certain estimates, judgments and assumptions that the Company believes are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. The accounting estimates, which IKONICS believes are the most critical to aid in fully understanding and evaluating its reported financial results, include the following:

Trade Receivables. The Company performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by review of the current credit information. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same collection history that has occurred in the past. The general payment terms are net 30-45 days for domestic customers and net 30-90 days for foreign customers. A small percentage of the trade receivables balance is denominated in a foreign currency with no concentration in any given country. At the end of each reporting period, the Company analyzes the receivable balance for customers paying in a foreign currency. These balances are adjusted to each quarter-end or year-end spot rate in accordance with guidance related to foreign currency matters.

Inventories. Inventories are valued at the lower of cost or market value using the last in, first out (LIFO) method. The Company monitors its inventory for obsolescence and records reductions in cost when required.

Income Taxes. At September 30, 2013, the Company had net current deferred tax assets of $142,000 and net noncurrent deferred tax liabilities of $431,000. The deferred tax assets and liabilities result primarily from temporary differences in property and equipment, accrued expenses, and inventory reserves. In connection with the recording of an impairment charge that occurred prior to 2012 related to an investment in a non-marketable equity security, the Company has recorded a deferred tax asset and corresponding full valuation allowance in the amount of $323,000 as it is more likely than not that this asset will not be realized. The fully reserved $323,000 deferred tax asset related to the capital loss can be carried forward one more year and must be offset by a capital gain. The Company has determined that it is more likely than not that the remaining deferred tax assets will be realized and that

Table of Contents

an additional valuation allowance for such assets is not currently required. The Company accounts for its uncertain tax positions under the provision of FASB ASC 740, Income Taxes. At September 30, 2013 the Company had no reserves for uncertain tax positions.

Revenue Recognition. The Company recognizes revenue on sales of products when title passes which can occur at the time of shipment or when the goods arrive at the customer location depending on the agreement with the customer. The Company sells its products to both distributors and end-users. Sales to distributors and end-users are recorded based upon the criteria governed by the sales, delivery, and payment terms stated on the invoices from the Company to the purchaser. In addition to transfer of title / risk of loss, all revenue is recorded in accordance with the criteria outlined within the provisions regarding revenue recognition including:

(a) persuasive evidence of an arrangement (principally in the form of customer sales orders and the Company’s sales invoices)

(b) delivery and performance (evidenced by proof of delivery, e.g. the shipment of film and substrates with bill of lading used for proof of delivery for FOB shipping point terms, and the carrier booking confirmation report used for FOB destination terms). Once the finished product is shipped and physically delivered under the terms of the invoice and sales order, the Company has no additional performance or service obligations to complete

(c) a fixed and determinable sales price (the Company’s pricing is established and is not based on variable terms, as evidenced in either the Company’s invoices or the limited number of distribution agreements; the Company rarely grants extended payment terms and has no history of concessions)

(d) a reasonable likelihood of payment (the Company’s terms are standard, and the Company does not have a substantial history of customer defaults or non-payment)

Sales are reported on a net basis by deducting credits, estimated normal returns and discounts. The Company’s return policy does not vary by geography. The Company is not under a warranty obligation and the customer has no rotation or price protection rights. Freight billed to customers is included in sales. Shipping costs are included in cost of goods sold.

Self-Funded Medical Insurance. The Company has a self-funded medical insurance plan and utilizes an administrative service company or a “third party administrator” to supervise and administer the program and act as the Company’s fiduciary and representative. The Company has reduced its risk under this self-funded plan by purchasing both specific and aggregate stop-loss insurance coverage for individual claims and total annual claims in excess of prescribed limits. The Company records estimates for claim liabilities based on information provided by the third-party administrators, historical claims experience, the life cycle of claims, expected costs of claims incurred but not paid, and expected costs to settle unpaid claims. The Company regularly monitors its estimated insurance-related liabilities. Actual claims experience may differ from the Company’s estimates. Costs related to the administration of the plan and related claims are expensed as incurred. The total liability for self-funded medical insurance was $45,000 as of September 30, 2013 and is included within other accrued expenses in the consolidated balance sheets.

Results of Operations

Quarter Ended September 30, 2013 Compared to Quarter Ended September 30, 2012

Sales. The Company realized a 0.3% sales decrease during the third quarter of 2013 with sales of $4.2 million, compared to $4.2 million in sales during the same period in 2012. The third quarter decrease is due to an $85,000 Micro-Machining sales decrease as both mask and machining sales were down for the quarter. The drop in

Table of Contents

mask sales is related to the loss of a large customer. Lower film and equipment sales resulted in an $84,000 IKONICS Imaging sales decrease. Third quarter 2012 IKONICS Imaging sales were favorably impacted by a large initial stocking order for a new customer. These sales decreases were partially offset by a 5.5%, or $98,000, Domestic sales increase as Domestic experienced improved sales across all product lines and a 4.3%, or $54,000, Export sales increase related to stronger Latin American sales. DTX also realized a 3.4% consumable sales increase.

Gross Profit. Gross profit was $1.6 million, or 38.9% of sales, in the third quarter of 2013 compared to $1.8 million, or 41.4% of sales, for the same period in 2012. Gross margins were unfavorably impacted by an increase in Micro-Machining production costs related to the Company’s efforts to improve its production capacity and capabilities and a decrease in sales volume as a large portion of Micro-Machining production costs are fixed. Additionally, the IKONICS Imaging gross profit decreased from 55.5% in the third quarter of 2012 to 52.6% due to a decrease in higher margin film sales. Export’s margin also decreased from 26.8% in third quarter of 2012 to 26.1% in the third quarter of 2013. The lower gross margins were partially offset by an improved Domestic gross margins related to a more favorable sales mix.

Selling, General and Administrative Expenses. Selling, general and administrative expenses were $1.3 million, or 31.5% of sales, in the third quarter of 2013, compared to $1.3 million, or 30.1% of sales, for the same period in 2012. The slight increase in selling, general and administrative expenses reflects higher selling and promotional expenses to support sales initiatives in the Domestic screen markets and increased Micro-Machining personnel costs related to improving and implementing new technologies. These increases have been partially offset by lower IKONICS Imaging and DTX selling expenses due to lower personnel costs.

Research and Development Expenses. Research and development expenses during the third quarter of 2013 were $150,000, or 3.6% of sales, versus $141,000, or 3.3% of sales, for the same period in 2012 due to increased staffing costs.

Interest Income. The Company earned $1,400 of interest income in the third quarter of 2013 compared to $2,600 of interest income in the third quarter of 2012. The interest earned in the third quarter of 2013 and 2012 is related to interest received from the Company’s short-term investments, which consists of fully insured certificates of deposit with original maturities ranging from three to twelve months.

Income Taxes. For the third quarter of 2013, the Company realized income tax expense of $47,000, or an effective rate of 28.7%, versus $113,000, or an effective rate of 33.1% for the third quarter of 2012. The income tax provision differs from the expected tax expense primarily due to the benefits of the domestic manufacturing deduction, research and development credits, and state income taxes.

Nine Months Ended September 30, 2013 Compared to the Nine Months Ended September 30, 2012

Sales. The Company’s sales increased 0.8% during the first nine months of 2013 to a record $12.9 million versus sales of $12.8 million during the first nine months of 2012. Export realized a 3.0% sales increase due to stronger sales to Asia which were partially offset by weaker sales to both Europe and Latin America. Additionally, Domestic posted a 3.0% sales increase for the first nine months of 2013 mainly due to both strong chemical and emulsion sales. These sales increases were partially offset by a 32% Micro-Machining sales decrease related to lower mask sales and a 1.3% IKONICS Imaging sales decrease. The IKONICS Imaging sales decrease is due to drop in both mask and film sales. The 4.1% nine month sales decrease in the DTX segment is related to the 2012 sale of a DTX printer. A DTX printer was not sold in the first nine months of 2013, however, increased DTX consumable sales partially offset the printer sales variance. The Company anticipates that most future DTX printer sales will be made directly by its strategic printer manufacturing partners and not the Company

Gross Profit. Gross profit for the first nine months of 2013 was $5.0 million, or 38.7% of sales, compared to $5.1 million, or 39.6% of sales, for the same period in 2012. Gross margins were unfavorably impacted by an increase in Micro-Machining production costs related to the Company’s efforts to improve its production capacity and capabilities and a decrease in sales volume as a large portion of Micro-Machining production costs are fixed.

Table of Contents

IKONICS Imaging gross margins for the first nine months of 2013 were also negatively impacted by a decrease in higher margin mask sales. These gross margin decreases were offset by a more favorable DTX and Export sales mix while Domestic margins for the first nine months of 2013 were similar to the first nine months of 2012.

Selling, General and Administrative Expenses. Selling, general and administrative expenses were $4.1 million, or 32.0% of sales, in the first nine months of 2013 compared to $4.0 million, or 31.2% of sales, for the same period in 2012. The increase in selling, general and administrative expenses reflects higher selling and promotional expenses to support sales initiatives in the Domestic screen markets and increased personnel costs for Micro-Machining related to improving and implementing new technologies. These increases have been partially offset by lower IKONICS Imaging and DTX selling expenses due to lower personnel costs.

Research and Development Expenses. Research and development expenses during the first nine months of 2013 were $476,000, or 3.7% of sales, versus $470,000, or 3.7% of sales, for the same period in 2012. The cost increase is related to higher personnel, supply and depreciation expenses. Research and development expense in the first nine months of 2012 was unfavorably impacted by a $22,000 abandonment of patent applications. The Company records patent application costs as an asset and amortizes those costs upon successful completion of the application process or expenses those costs when an application is abandoned. There were no expenses related to the abandonment of patent application costs in the first nine months of 2013.

Interest Income. The Company earned $5,300 of interest income during the first nine months of 2013 compared to $9,400 of interest income for the same period in 2012. The interest earned in the first nine months of 2013 and 2012 is related to interest received from the Company’s short-term investments, which consists of fully insured certificates of deposit with maturities ranging from three to twelve months.

Income Taxes. For the first nine months of 2013, the Company realized income tax expense of $73,000, or an effective rate of 18.5%, compared to income tax expense of $207,000, or an effective rate of 33.6%, for the same period in 2012. The Company’s income tax expense for the first nine months of 2013 was favorably impacted by 2012 tax law changes related to research and development credits and depreciation. These tax law changes were implemented in the first quarter of 2013 and were not allowed to be included in the Company’s 2012 tax provision under Generally Accepted Accounting Principles. Accordingly, the benefits from these 2012 tax law changes were recognized in the first quarter of 2013. The Company expects that for the remainder of 2013, it will record the provision for income taxes at an effective tax rate of 28%, as it recognizes benefits from the domestic manufacturing deduction, research and development credits, and state income taxes.

Liquidity and Capital Resources

The Company has financed its operations principally with funds generated from operations. These funds have been sufficient to cover the Company’s normal operating expenditures, annual capital requirements, and research and development expenditures.

Cash and cash equivalents were $1,179,000 and $968,000 at September 30, 2013 and December 31, 2012, respectively. Operating activities provided $1,151,000 in cash to the Company during the first nine months of 2013 compared to $567,000 of cash provided by operating activities during the same period in 2012. Cash provided by operating activities is primarily the result of net income adjusted for non-cash depreciation, amortization, and certain changes in working capital components discussed in the following paragraph.

During the first nine months of 2013, trade receivables decreased by $161,000. The decrease in receivables was driven by improved collections. Inventories decreased by $163,000 due to lower finished good inventory levels. Prepaid expenses and other assets increased $11,000 reflecting the timing of prepaid insurance premiums. Accounts payable increased $66,000 due to of the timing of payments to vendors. Accrued expenses increased $83,000, reflecting the timing of compensation payments. Income taxes receivable increased $92,000 and income taxes payable decreased $69,000 due to the timing of estimated tax payments compared to the calculated 2013 tax liability.

Table of Contents

During the first nine months of 2012, inventories increased by $340,000 due to increased raw material purchases. The higher raw material purchases are due to the Company’s efforts to take advantage of volume discounts and to protect against future price increases. The trade receivables increase of $87,000 was related to slightly slower collections. The Company believes that the quality of its receivables is high and that strong internal controls are in place to maintain proper collections. Deposits, prepaid expenses and other assets increased $87,000, due to deposits related to sales and marketing initiatives and insurance premiums paid in advance of the third quarter of 2012. Accounts payable decreased $43,000 due to of the timing of payments. Income taxes receivable decreased $59,000 and income taxes payable increased $90,000 due to the timing of estimated 2012 tax payments compared to the calculated 2012 tax liability. Accrued expenses increased $127,000, reflecting the timing of compensation payments and accrued medical expenses.

During the first nine months of 2013, cash used from investing activities was $1,003,000. Ten certificates of deposit totaling $1,443,000 matured during the first nine months of 2013 while the Company invested in twelve certificates of deposits totaling $1,815,000 in the same period. Additionally, the Company realized $25,000 from the disposal of a vehicle. The Company’s purchases of equipment for the first nine months of 2013 were $586,000. These purchases include equipment to improve Micro-Machining capabilities along with upgrades to research and development equipment and facilities, including improvements to both DTX equipment and equipment and facilities related to screen printing and IKONICS Imaging in addition to a vehicle for sales personnel. Also during the first nine months of 2013, the Company incurred $69,000 in patent application costs that the Company records as an asset and amortizes upon successful completion of the application process.

During the first nine months of 2012, investing activities used $215,000. Purchases of property and equipment were $372,000, mainly for manufacturing equipment and mandatory elevator upgrades. Also during the first nine months of 2012, the Company incurred $30,000 in patent application costs that the Company records as an asset and amortizes upon successful completion of the application process. The Company also invested $1,650,000 in eleven fully insured certificates of deposit during the first nine months of 2012. Nine certificates of deposit totaling $1,838,000 matured during the first nine months of 2012.

During the first nine months of 2013, the Company received $63,000 from financing activities from the issuance of 10,361 shares of common stock from the exercise of stock options compared to $30,000 the Company received from the issuance of 5,700 shares of common stock from the exercise of stock options in the first nine months of 2012.

A bank line of credit exists providing for borrowings of up to $1,250,000 through May 31, 2015 if not renewed. Outstanding debt under this line of credit is collateralized by trade receivables and inventories and bears interest at 2.5 percentage points over the 30-day LIBOR rate. The Company did not utilize this line of credit during the first nine months of 2013 and there were no borrowings outstanding as of September 30, 2013. The line of credit was also not utilized during the first nine months of 2012, and there were no borrowings outstanding under this line as of September 30, 2012. There are no financial covenants related to the line of credit.

The Company believes that current financial resources, its line of credit, cash generated from operations and the Company’s capacity for debt and/or equity financing will be sufficient to fund current and anticipated business operations. The Company also believes that its low debt levels and available line of credit make it unlikely that a decrease in demand for the Company’s products would impair the Company’s ability to fund operations.

Capital Expenditures

Through the first nine months of 2013, the Company had $586,000 in capital expenditures. These purchases include equipment to improve Micro-Machining capabilities along with upgrades to research and development equipment and facilities, including improvements to both DTX equipment, and equipment and facilities related to screen printing and IKONICS Imaging, in addition to a vehicle for sales personnel. Plans for capital expenditures include additional manufacturing equipment upgrades and a vehicle for a sales person. These commitments are expected to be funded with cash generated from operating activities and cash on hand.

Table of Contents

International Activity

The Company markets its products to numerous customers located in North America, Europe, Latin America, Asia and other parts of the world. Foreign sales were approximately 33% of total sales during the first nine months of 2013 and 32% during the first nine months of 2012. Higher volumes in Asia positively impacted 2013 first nine months sales volumes as compared to lower volumes in Europe and Latin America. Fluctuations of certain foreign currencies have not significantly impacted the Company’s operations because the Company’s foreign sales are not concentrated in any one region of the world and the majority of international sales are conducted in U.S. dollars. The Company believes its vulnerability to uncertainties due to foreign currency fluctuations and general economic conditions in foreign countries is not significant.

The Company’s foreign transactions are primarily negotiated, invoiced and paid in U.S. dollars, while a portion is transacted in Euros. The Company has not implemented an economic hedging strategy to reduce the risk of foreign currency translation exposures, which management does not believe to be significant based on the scope and geographic diversity of the Company’s foreign operations as of September 30, 2013. Furthermore, the impact of foreign exchange on the Company’s balance sheet and operating results was not material in either 2013 or 2012.

Future Outlook

IKONICS has spent on average approximately 4% of its sales dollars for the past few years in research and development and has made capital expenditures related to its DTX and Micro-Machining programs. The Company plans to maintain its efforts in this area and expedite internal product development as well as form technological alliances with outside experts to commercialize new product opportunities.

The Company continues to make progress on its new Micro-Machining business initiative. The Company has entered into agreements with several major aerospace companies to determine the feasibility of using its unique technologies in the production of military and commercial aircraft. The Company is currently supplying products to the aerospace industry for use in the construction of new generation commercial aircraft. Although sequestration of the Department of Defense budget and delays in the launching of new commercial aircraft fleets could adversely affect some of these sales, progress is being made on a number of in-house feasibility projects, and the Company believes that several of these could lead to ongoing business. In anticipation of this business, the Company is expanding its Micro-Machining capacity and patent applications.

The Company is also continuing to make progress on its DTX business initiatives. In addition to its growing inkjet technology business, the Company offers a range of products for creating texture surfaces and has introduced a fluid for use in prototyping. The Company is currently working with its DTX customers on training, production optimization, and product improvements. The Company has been awarded European, Japanese and United States patents on its DTX technologies.

Domestically, both the Domestic Chromaline Screen Print Product and the IKONICS Imaging units remain profitable mature markets and require aggressive strategies to grow market share. Although there will be challenges, the Company believes these businesses will continue to grow and be profitable. In addition to its traditional emphasis on domestic markets, the Company will continue efforts to grow its business internationally by attempting to develop new markets and expanding market share where it has already established a presence.

Other future activities undertaken to expand the Company’s business may include acquisitions, building improvements, equipment additions, new product development and marketing opportunities.

Recent Accounting Pronouncements

The Company does not expect that the adoption of any recent accounting pronouncements will have a material impact on its financial statements.

Off Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings

None

ITEM 1A. Risk Factors

Not applicable

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable

ITEM 3. Defaults upon Senior Securities

Not applicable

ITEM 4. Mine Safety Disclosures

Not applicable

ITEM 5. Other Information

None

ITEM 6. Exhibits

The following exhibits are filed as part of this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2013:

Exhibit		Description
3.1		Restated Articles of Incorporation of Company, as amended.(1)
3.2		By-Laws of the Company, as amended.(2)
31.1		Rule 13a-14(a)/15d-14(a) Certifications of CEO
31.2		Rule 13a-14(a)/15d-14(a) Certifications of CFO
32		Section 1350 Certifications
101		Interactive Data Files Pursuant to Rule 405 of Regulation S-T

Copies of Exhibits will be furnished upon request and payment of the Company’s reasonable expenses in furnishing the Exhibits.

(1) Incorporated by reference to the like numbered Exhibit to the Company’s Registration Statement on Form 10-SB (File No. 000-25727).

(2) Incorporated by reference to the like numbered Exhibit to the Company’s Current Report on Form 8-K filed with the Commission on February 22, 2007 (File No. 000-25727).

		PAGE NO.

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements:

	Condensed Balance Sheets as of September 30, 2013 (unaudited) and December 31, 2012	3

	Condensed Statements of Income for the Three Months and Nine Months Ended September 30, 2013 and 2012 (unaudited)	4

	Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2013 and 2012 (unaudited)	5

	Notes to Condensed Financial Statements (unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	19

Item 4.	Controls and Procedures	19

PART II.	OTHER INFORMATION	20

	SIGNATURES	21

	IKONICS CORPORATION


DATE: November 14, 2013	By:	/s/ Jon Gerlach
		Jon Gerlach,
		Chief Financial Officer, and
		Vice President of Finance

Exhibit	Description	Page
3.1	Restated Articles of Incorporation of Company, as amended	Incorporated by reference
3.2	By-Laws of the Company, as amended	Incorporated by reference
31.1	Rule 13a-14(a)/15d-14(a) Certifications of CEO	Filed Electronically
31.2	Rule 13a-14(a)/15d-14(a) Certifications of CFO	Filed Electronically
32	Section 1350 Certifications	Filed Electronically
101	Interactive Data Files Pursuant to Rule 405 of Regulation S-T	Filed Electronically